benzyl (1R,5R)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate | 370881-68-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl (1R,5R)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate
• 英文别名: (1R,5R)-benzyl 3,6-diazabicyclo[3.2.0]heptane-3-carboxylate；(1R,5R)-3-benzyloxycarbonyl-3,6-diazabicyclo[3.2.0]heptane；(1R,5R)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylic acid benzyl ester；cis-3,6-Diazabicyclo[3.2.0]heptane-3-carboxylic acid benzyl ester
• CAS: 370881-68-8
• 化学式: C₁₃H₁₆N₂O₂
• 分子量: 232.282
• InChiKey: BCONCMOUSFKNCK-NEPJUHHUSA-N

物化性质

• 沸点：
  370.7±25.0 °C(Predicted)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl (1R,5R)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate 在 tris(dibenzylideneacetone)dipalladium (0) caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 、 三氟乙酸 为溶剂， 反应 41.0h， 生成 5-[(1S,5R)-3,6-diazabicyclo[3.2.0]heptan-6-yl]nicotinonitrile
  参考文献：
  名称：

  A-366833: A novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane α4β2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models

  摘要：

  5-[(1R,5S)-3,6-Diazabicyclo[3.2.0]heptan-6-yl]nicotinonitrile (A-366833) is a novel nicotinic acetylcholine receptor (nAChR) ligand that binds to the agonist-binding site ([H-3]-cytisine) with K-i value of 3.1 nM and exhibits agonist selectivity at alpha 4 beta 2 nAChR relative to the alpha 3 beta 4 nAChR subtype. The analgesic effects of A-366833 were examined across a variety of animal models including the mouse model of writhing pain (abdominal constriction), the rat models of acute thermal (hot box), persistent chemical (formalin) and neuropathic (spinal nerve ligation, SNL) pain. In the abdominal constriction model, A-366833 was effective at doses ranging from 0.062 to 0.62 mu mol/kg (i.p.). In addition, A-366833 demonstrated significant effects in acute thermal pain (6.2-19.0 mu mol/kg, i.p.), formalin (1.9-19 mu mol/kg i.p.) and SNL (1.9-19 mu mol/kg i.p.) models. The systemic effects of A-366833 were attenuated by pretreatment with mecamylamine (5 mu mol/kg i.p.) in both the formalin and SNL models, suggesting that the analgesic effects of A-366833 in models of persistent nociceptive and neuropathic pain are mediated by activation of nAChRs. Pharmacokinetic investigations of A-366833 in rat revealed moderate brain:plasma distribution, half-life of 1.5 h and excellent oral bioavailability of 73%. Comparison of peak plasma levels at the minimal effective doses across rat models of acute thermal pain, formalin and SNL with the maximal exposure that does not evoke emesis in ferret revealed therapeutic margins ranging from 6- to 22-fold. These studies indicate that compounds like A-366833 with improved agonist selectivity at alpha 4 beta 2 vs. alpha 3 beta 4 nAChR can elicit a broad spectrum of analgesic efficacy without concurrent adverse effects. (C) 2007 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bcp.2007.08.010
• 作为产物：
  描述：

  benzyl (3R,4R)-3-tert-butoxycarbonylamino-4-methylsulfonyloxymethyl-pyrrolidine-1-carboxylate 以69%的产率得到benzyl (1R,5R)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate
  参考文献：
  名称：

  Diazabicyclic central nervous system active agents

  摘要：

  式I1的化合物，这些化合物的药物组合物，以及利用这些组合物来控制哺乳动物的突触传递。

  公开号：

  US20020019388A1

文献信息

• Amino-substituted tricyclic derivatives and methods of use
  申请人：Schrimpf R. Michael

  公开号：US20050234031A1

  公开（公告）日：2005-10-20

  Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y 1 and Y 2 form various tricyclic cores, X a and X b are C, CH, or N, as defined herein, and R x is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives. Methods of using amino-substituted tricyclic derivatives also are described herein.

  式（I）的化合物 其中A和B是胺基取代的侧链，Y 1 和Y 2 形成各种三环核，X a 和X b 为C、CH或N，如本文所定义，R x 是可选的取代基。考虑到式（I）的化合物和组合物，以及用于治疗由α7nAChR配体预防或改善的疾病或疾病的方法，这些方法涵盖了式（I）的化合物和其他三环衍生物。本文还描述了使用氨基取代的三环衍生物的方法。
• Substituted diazabicycloakane derivatives
  申请人：Basha Anwer

  公开号：US20050065178A1

  公开（公告）日：2005-03-24

  Compounds of formula (I) Z-Ar 1 —Ar 2 (I) wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from an unsubstituted or substituted 5-membered heteroaryl ring; an unsubstituted or substituted 6-membered heteroaryl ring; 3,4-(methylenedioxy)phenyl; and phenyl substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

  式(I)的化合物 Z-Ar 1 —Ar 2 (I) 其中Z是一种二氮杂双环胺，Ar 1 是一个5-或6-成员芳香环，Ar 2 从未取代或取代的5-成员杂芳基环；一个未取代或取代的6-成员杂芳基环；3,4-(亚甲二氧基)苯基；和苯基在间位或对位上取代有0、1、2或3个取代基。这些化合物在治疗由α7 nAChR配体预防或改善的病症或紊乱方面是有用的。还公开了包括式(I)的化合物的药物组合物以及使用这些化合物和组合物的方法。
• Antibacterial compounds
  申请人：——

  公开号：US20030232818A1

  公开（公告）日：2003-12-18

  Antibacterials having formula (I) 1 and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.

  抗菌剂的化学式（I）及其盐、前药、前药的盐，制备这些化合物的方法和用于制备过程中使用的中间体，含有这些化合物的组合物，以及使用这些化合物进行细菌感染的预防和治疗方法被披露。
• Synthesis and Structure−Activity Relationship Studies of 3,6-Diazabicyclo[3.2.0]heptanes as Novel α4β2 Nicotinic Acetylcholine Receptor Selective Agonists
  作者：Jianguo Ji、Michael R. Schrimpf、Kevin B. Sippy、William H. Bunnelle、Tao Li、David J. Anderson、Connie Faltynek、Carol S. Surowy、Tino Dyhring、Philip K. Ahring、Michael D. Meyer

  DOI：10.1021/jm070755h

  日期：2007.11.1

  influences of the 3,6-diazabicyclo[3.2.0]heptane core. Small 5-substituents on the pyridine ring had a modest impact on the binding affinities and functional activities. 6-Bromo, 6-chloro, and 6-methyl substituents on the pyridine ring led to increased binding affinities and improved functional activities. Most of the 6-N-pyridinyl-substituted 3,6-diazabicyclo[3.2.0]heptanes are selective for the alpha4beta2

  合成了一系列从3,6-二氮杂双环[3.2.0]庚烷衍生的新型有效神经元烟碱乙酰胆碱受体（nAChR）配体，并评估了其对alpha4beta2 nAChR亚型的结合亲和力和激动剂活性。这些新型nAChR配体的结构活性关系研究集中于对吡啶环的取代作用以及3,6-二氮杂双环[3.2.0]庚烷核心的立体和区域化学影响。吡啶环上的5个小取代基对结合亲和力和功能活性影响不大。吡啶环上的6-溴，6-氯和6-甲基取代基导致增加的结合亲和力和改善的功能活性。大多数6-N-吡啶基取代的3,6-二氮杂双环[3.2.0]庚烷对alpha4beta2 nAChR亚型具有选择性。化合物（1R，5S）-25，（1R，5S）-55，和（1R，5S）-56在halpha3beta4 nAChR上几乎没有活性，但在halpha4beta2 nAChR亚型上保留了效力和功效。3-N-吡啶基取代的系列显示出更复杂的SAR。发现（
• 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES
  申请人：Black Lawrence A.

  公开号：US20100331294A1

  公开（公告）日：2010-12-30

  Compounds of the formula wherein R 1 and R 2 are as disclosed herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor full or partial agonists. Also disclosed are pharmaceutical compositions, methods for using such compounds and compositions, and processes for preparing the compounds.

  其中R1和R2如本文所披露的那样的化合物，在治疗通过组胺-3受体的全或部分激动剂预防或缓解的病症或疾病中是有用的。还披露了药物组合物、使用这类化合物和组合物的方法，以及制备这类化合物的过程。